The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Philip Kern
96 participants
Dec 13, 2021
INTERVENTIONAL
Conditions
Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Eligibility
Inclusion Criteria2
- Hemoglobin A1C between 5.7 and 6.4
- Body mass index between 27 and 45
Exclusion Criteria8
- Diabetes
- Chronic use of any antidiabetic medications
- Any unstable medical condition
- Use of steroids or daily use of NSAIDS
- History of chronic inflammatory conditions
- Use of anticoagulants
- Contraindications to the use of mirabegron or tadalafil
- Any condition deemed risky by the study physician
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Mirabegron 50 mg/day will be administered for 14 weeks.
Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
Placebo will be administered for 14 weeks after baseline procedures.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05051436